​The University of Jordan (UJ) announced the launch of the "Microneedle Drug Delivery" research group, dedicated to developing innovative and painless transdermal drug delivery systems. The initiative aims to improve the treatment of chronic and serious diseases such as cancer, diabetes, autoimmune disorders, and infectious diseases by creating biocompatible microneedles capable of delivering therapeutic agents with high precision and efficiency.

The research group will focus on optimize microneedles for reliable skin penetration, analyzing degradation profiles and drug release rates, and conducting preliminary animal studies. Integrating advanced materials and scalable manufacturing techniques, the group will develop microneedles for effective localized drug, vaccine, and immunotherapy delivery, minimizing invasive medical interventions.

The Microneedle Drug Delivery research group's efforts will focus on: Designing and developing specialized microneedles for targeted and efficient drug delivery, enhancing efficiency of drugs through advanced delivery systems, and conducting preclinical and clinical studies to assess safety and efficacy of drug delivery technologies.

The distinguished team includes Prof. Sharif Abdelghany (University of Jordan), Dr. Yazan Al Thaher (Philadelphia University), Dr. Samir Jabaiti (School of Medicine, University of Jordan), Dr. Khaled Khraisat (founder of the platform for integrating academia with industry in Amman), Dr. Rahamatullah Shaikh (Faculty of Pharmacy, University of Bradford, UK), Pharmacist Emad Badwan (Ministry of Health, Amman), Dr. Roger Narayan (University of North Carolina, USA), Prof. Ryan Donnelly (Queen's University Belfast, UK), and Pharmacist Ayman Abbas (School of Pharmacy, University of Jordan).

This initiative underscores UJ's commitment to applied research and its dedication to developing innovative medical technologies that will improve healthcare.

For more:

https://research.ju.edu.jo/research/groups/MNDD/home.aspx